Two thirds of Coronavirus patients improve after Gilead drugFILE PHOTO: A Gilead Sciences Inc. office is shown in Foster City, California, US May 1, 2018. Gilead last month sharply limited its compassionate use programme for remdesivir and is conducting its own clinical trials of the antiviral drug, with results expected in coming weeks. Researchers in China, as well as the US National Institutes of Health, are also testing the drug in Covid-19 patients. The new analysis includes patients in the United States, Europe, Canada and Japan who received a 10-day course of intravenous remdesivir. Read Now »Twelve patients, 23 per cent, had serious side effects including multiple-organ-dysfunction syndrome, septic shock and acute kidney injury.

Source: Standard Digital April 12, 2020 18:22 UTC